Voyageur Pharmaceuticals Ltd. (VM.V)
CAD 0.11
(50.0%)
CAD 0.11
(50.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 37.91 Thousand CAD | 727.63% |
| 2022 | -6041.00 CAD | 99.22% |
| 2021 | -770.89 Thousand CAD | -390.42% |
| 2020 | 265.44 Thousand CAD | 321.23% |
| 2019 | 63.01 Thousand CAD | 92.52% |
| 2018 | 32.73 Thousand CAD | -0.28% |
| 2017 | 32.82 Thousand CAD | 104.71% |
| 2016 | -696.99 Thousand CAD | -680.02% |
| 2015 | -89.35 Thousand CAD | 44.15% |
| 2014 | -160 Thousand CAD | 12.88% |
| 2013 | -183.66 Thousand CAD | 22.96% |
| 2012 | -238.39 Thousand CAD | -52.02% |
| 2011 | -156.81 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 26.83 Thousand CAD | 112.79% |
| 2024 Q1 | -209.75 Thousand CAD | -653.22% |
| 2024 Q3 | -3035.00 CAD | 37.77% |
| 2023 Q2 | -98.58 Thousand CAD | 84.26% |
| 2023 Q3 | 23.63 Thousand CAD | 123.98% |
| 2023 Q4 | 37.91 Thousand CAD | 60.4% |
| 2023 FY | 37.91 Thousand CAD | 727.63% |
| 2023 Q1 | -626.41 Thousand CAD | -10269.39% |
| 2022 Q3 | -230.25 Thousand CAD | -13.48% |
| 2022 Q4 | -6041.00 CAD | 97.38% |
| 2022 FY | -6041.00 CAD | 99.22% |
| 2022 Q1 | -282.74 Thousand CAD | 63.32% |
| 2022 Q2 | -202.9 Thousand CAD | 28.24% |
| 2021 Q1 | -318.8 Thousand CAD | -220.1% |
| 2021 Q2 | -1.63 Million CAD | -413.74% |
| 2021 Q3 | -1.41 Million CAD | 13.54% |
| 2021 Q4 | -770.89 Thousand CAD | 45.56% |
| 2021 FY | -770.89 Thousand CAD | -390.42% |
| 2020 Q3 | 207.74 Thousand CAD | 13.33% |
| 2020 Q2 | 183.3 Thousand CAD | 151.88% |
| 2020 Q1 | 72.77 Thousand CAD | 15.49% |
| 2020 FY | 265.44 Thousand CAD | 321.23% |
| 2020 Q4 | 265.44 Thousand CAD | 27.77% |
| 2019 Q2 | 111.41 Thousand CAD | -35.35% |
| 2019 FY | 63.01 Thousand CAD | 92.52% |
| 2019 Q4 | 63.01 Thousand CAD | 12.14% |
| 2019 Q3 | 56.19 Thousand CAD | -49.56% |
| 2019 Q1 | 172.32 Thousand CAD | 426.47% |
| 2018 Q3 | 106.81 Thousand CAD | 203.34% |
| 2018 Q1 | 871.00 CAD | -97.35% |
| 2018 FY | 32.73 Thousand CAD | -0.28% |
| 2018 Q4 | 32.73 Thousand CAD | -69.36% |
| 2018 Q2 | 35.21 Thousand CAD | 3942.71% |
| 2017 Q3 | -110.39 Thousand CAD | 42.92% |
| 2017 FY | 32.82 Thousand CAD | 104.71% |
| 2017 Q4 | 32.82 Thousand CAD | 129.73% |
| 2017 Q1 | -351.00 CAD | 99.95% |
| 2017 Q2 | -193.4 Thousand CAD | -55000.85% |
| 2016 FY | -696.99 Thousand CAD | -680.02% |
| 2016 Q3 | -70.25 Thousand CAD | 4.97% |
| 2016 Q2 | -73.92 Thousand CAD | 15.49% |
| 2016 Q4 | -696.99 Thousand CAD | -892.1% |
| 2016 Q1 | -87.47 Thousand CAD | 2.11% |
| 2015 Q4 | -89.35 Thousand CAD | 2.53% |
| 2015 Q2 | -94.48 Thousand CAD | 40.18% |
| 2015 Q1 | -157.94 Thousand CAD | 1.29% |
| 2015 FY | -89.35 Thousand CAD | 44.15% |
| 2015 Q3 | -91.67 Thousand CAD | 2.97% |
| 2014 Q4 | -160 Thousand CAD | 0.55% |
| 2014 Q1 | -177.79 Thousand CAD | 3.2% |
| 2014 Q2 | -178.29 Thousand CAD | -0.28% |
| 2014 Q3 | -160.89 Thousand CAD | 9.76% |
| 2014 FY | -160 Thousand CAD | 12.88% |
| 2013 Q2 | -223.68 Thousand CAD | 6.22% |
| 2013 Q4 | -183.66 Thousand CAD | 13.17% |
| 2013 FY | -183.66 Thousand CAD | 22.96% |
| 2013 Q3 | -211.52 Thousand CAD | 5.44% |
| 2013 Q1 | -238.51 Thousand CAD | -0.05% |
| 2012 FY | -238.39 Thousand CAD | -52.02% |
| 2012 Q2 | -258.71 Thousand CAD | 0.0% |
| 2012 Q4 | -238.39 Thousand CAD | 2.9% |
| 2012 Q3 | -245.5 Thousand CAD | 5.11% |
| 2011 FY | -156.81 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aequus Pharmaceuticals Inc. | 4.89 Million CAD | 99.225% |
| CanadaBis Capital Inc. | 4.08 Million CAD | 99.072% |
| Decibel Cannabis Company Inc. | 37.48 Million CAD | 99.899% |
| Delivra Health Brands Inc. | -2.17 Million CAD | 101.745% |
| Entourage Health Corp. | 150.32 Million CAD | 99.975% |
| Lifeist Wellness Inc. | -188.12 Thousand CAD | 120.154% |
| Cannara Biotech Inc. | 41.51 Million CAD | 99.909% |
| Medicure Inc. | -5.82 Million CAD | 100.651% |
| PharmaCielo Ltd. | 18.24 Million CAD | 99.792% |
| Rubicon Organics Inc. | 475.37 Thousand CAD | 92.024% |
| BioSyent Inc. | -3.68 Million CAD | 101.029% |